Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1998 1
2000 1
2004 1
2005 1
2006 2
2007 1
2013 2
2015 1
2016 3
2020 1
2021 1
2023 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Clinical, laboratory and ultrasonographic findings at baseline predict long-term outcome of polymyalgia rheumatica: a multicentric retrospective study : Polymyalgia rheumatica predicted by ultrasonographic findings polymyalgia rheumatica outcome predicted early by ultrasound.
Conticini E, Falsetti P, d'Alessandro M, Al Khayyat SG, Grazzini S, Baldi C, Acciai C, Gentileschi S, D'Alessandro R, Bellisai F, Biasi G, Barreca C, Bargagli E, Cantarini L, Frediani B. Conticini E, et al. Among authors: barreca c. Intern Emerg Med. 2023 Oct;18(7):1929-1939. doi: 10.1007/s11739-023-03373-x. Epub 2023 Jul 27. Intern Emerg Med. 2023. PMID: 37498353 Free PMC article.
COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs.
Conticini E, Bargagli E, Bardelli M, Rana GD, Baldi C, Cameli P, Gentileschi S, Bennett D, Falsetti P, Lanzarone N, Bellisai F, Barreca C, D'Alessandro R, Cantarini L, Frediani B. Conticini E, et al. Among authors: barreca c. Ann Rheum Dis. 2021 Feb;80(2):e14. doi: 10.1136/annrheumdis-2020-217681. Epub 2020 May 15. Ann Rheum Dis. 2021. PMID: 32414804 No abstract available.
Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseasesResponse to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677-1683.
Gentileschi S, Barreca C, Bellisai F, Biasi G, Brizi MG, De Stefano R, Fabbroni M, Fioravanti A, Frati E, Selvi E, Vitale A, Cantarini L, Frediani B, Galeazzi M. Gentileschi S, et al. Among authors: barreca c. Expert Opin Biol Ther. 2016 Oct;16(10):1311-2. doi: 10.1080/14712598.2016.1198765. Epub 2016 Jun 28. Expert Opin Biol Ther. 2016. PMID: 27266338 No abstract available.
Characterization of VP22 in herpes simplex virus-infected cells.
Mouzakitis G, McLauchlan J, Barreca C, Kueltzo L, O'Hare P. Mouzakitis G, et al. Among authors: barreca c. J Virol. 2005 Oct;79(19):12185-98. doi: 10.1128/JVI.79.19.12185-12198.2005. J Virol. 2005. PMID: 16160145 Free PMC article.
16 results